反応式
[CH2:1]([OH:5])[C:2](=[CH2:4])[CH3:3].F[C:7]1[CH:8]=[C:9]([CH3:16])[CH:10]=[CH:11][C:12]=1[N+:13]([O-:15])=[O:14].[CH3:17][C:18]1[CH:24]=[CH:23][C:21]([NH2:22])=[C:20]([O:25][CH2:26][C:27]([CH3:29])=[CH2:28])[CH:19]=1.[NH2:30][C:31]1[S:32][CH:33]=[CH:34][N:35]=1>>[CH3:4][C:2](=[CH2:3])[CH2:1][O:5][C:7]1[CH:8]=[C:9]([CH3:16])[CH:10]=[CH:11][C:12]=1[N+:13]([O-:15])=[O:14].[CH3:17][C:18]1[CH:24]=[CH:23][C:21]([NH:22][C:1]([NH:30][C:31]2[S:32][CH:33]=[CH:34][N:35]=2)=[O:5])=[C:20]([O:25][CH2:26][C:27]([CH3:29])=[CH2:28])[CH:19]=1参加物
6
実験手順
3-(2-Methyl-allyloxy)-4-nitrotoluene (0.78 g, 75%) was prepared from methallyl alcohol and 3-fluoro-4-nitrotoluene (0.77 g, 5.0 mmol) following the general procedure G. This was reduced to 4-methyl-2-(2-methyl-allyfoxy)aniline (0.47 g, 70%) following general procedure B. 1-[4-Methyl-2-(2-methyl-allyloxy)-phenyl]-3-thiazol-2-yl-urea (210 mg, 70%) was prepared from 4-methyl-2-(2-methyl-allyloxy)aniline (179 mg, 1.0 mmol) and 2-aminothiazole (100 mg, 1.0 mmol) following the general procedure D.
出典と根拠
- ORDレコード
- ord-25995062b3c74c8cb170a8f08ba7950e
- 出典データセット
- uspto-grants-2008_06
- 特許番号
- US07384967B2
関連ノート
読み込み中…